FY2029 Earnings Forecast for MNPR Issued By HC Wainwright

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Investment analysts at HC Wainwright issued their FY2029 EPS estimates for shares of Monopar Therapeutics in a research report issued to clients and investors on Wednesday, January 22nd. HC Wainwright analyst S. Lee anticipates that the company will post earnings of $3.66 per share for the year. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.09.

A number of other analysts have also recently commented on the stock. Piper Sandler began coverage on shares of Monopar Therapeutics in a research note on Friday, January 10th. They issued an “overweight” rating and a $72.00 target price for the company. Rodman & Renshaw began coverage on shares of Monopar Therapeutics in a research note on Friday, October 11th. They issued a “buy” rating and a $50.00 target price for the company.

Monopar Therapeutics Stock Up 16.8 %

Shares of Monopar Therapeutics stock opened at $39.32 on Thursday. The firm’s 50 day moving average price is $23.76 and its 200-day moving average price is $12.15. The company has a market cap of $239.85 million, a P/E ratio of -19.96 and a beta of 1.23. Monopar Therapeutics has a 52-week low of $1.54 and a 52-week high of $39.99.

Insider Activity

In other Monopar Therapeutics news, CFO Karthik Radhakrishnan acquired 1,550 shares of the company’s stock in a transaction dated Monday, October 28th. The shares were acquired at an average cost of $16.25 per share, with a total value of $25,187.50. Following the acquisition, the chief financial officer now directly owns 1,550 shares of the company’s stock, valued at approximately $25,187.50. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 34.90% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.